National Health (Pharmaceutical Benefits) Regulations (Cth)

STATUTORY RULES.

1954. No. 54

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

Dated this twelfth

day of May , 1954.

Deputy of the Governor-General.

By His Excellency’s Command,

Minister of State for Health.

National Health (Pharmaceutical Benefits) Regulations.

Citation.

1. These Regulations may be cited as the National Health (Pharmaceutical Benefits) Regulations.

Interpretation.

2.—(1.) In these Regulations, unless the contrary intention appears—

“authorized form” means a form authorized by the Director-General;

“authorized prescription form” means a paper, not less than five or more than six inches in length and not less than three or more than four inches in breadth, on which appear the name and address of a medical practitioner and at the top of which are written the letters “N.H.S.” and, in the case of a prescription written for a pensioner pharmaceutical benefit, the words “Pensioner Benefit”;
“entitlement card” means an entitlement card issued by the Commonwealth to a pensioner for the purposes of Part IV. and Part VII. of the Act;
“pensioner pharmaceutical benefit” means a pensioner pharmaceutical benefit under paragraph (b) of sub-section (1.) of section 85 of the Act as affected by regulations 9, 10 and 11 of these Regulations;
“pension number”, in relation to a pensioner, means his pension number appearing on his entitlement card;
“the Act” means the National Health Act 1953;

* Notified in the Commonwealth Gazette on , 1954.

1441.—Price 10/5.5.1954.

“the Australian Pharmaceutical Formulary” means the latest edition for the time being of the hook called the Australian and New Zealand Pharmaceutical Formulary published by the Australian and New Zealand Pharmaceutical Association, or, if that edition has been added to or amended, that edition as affected by those additions or amendments;
“the British Pharmaceutical Codex” means the latest edition for the time being of the book called the British Pharmaceutical Codex published by direction of the Council of the Pharmaceutical Society of Great Britain, or, if that edition has been added to or amended, that edition as affected by those additions or amendments;
“the British Pharmacopoeia (1948)” means the edition of the book called the British Pharmacopoeia published under the direction of the General Medical Council of the United Kingdom in the year 1948 as affected by the additions or amendments contained in the 1951 Addendum to that book;
“the United States Pharmacopoeia” means the latest edition for the time being of the book called the Pharmacopoeia of the United States of America prepared by the Committee of Revision and published by authority of the United States Pharmacopoeia Convention, or, if that edition has been added to or amended, that edition as affected by those additions or amendments;
“trading hours”, in relation to an approved pharmaceutical chemist, means his trading hours established by or under the law of the State or Territory in which his premises are situated.

(2.) For the purposes of these Regulations—

(a) the abbreviations appearing in the columns headed “Strength” and “Form of Unit” in the First and Second Schedules have the following meanings:—

“amp.” means ampoule;

“cc.” means cubic centimetres;

“fl. oz.” means fluid ounces of 480 minims;

“G.” means grammes;

“γ” means microgrammes;

“gr.” means grains;

“hypo, tab.” means hypodermic tablet;

“I.M.” means intramuscular;

“I.U.” means international units determined in the year 1950 by the Expert Committee on Biological Standardisation of the World Health Organisation;

“I.V.” means intravenous;

“mg.” means milligrammes;

“M.” means millions of organisms;

“mil.” means millilitres;

“min.” means minims;

“U.” means units;

“U.S.P.” means the United States Pharmacopoeia; and

(b)the letters appearing in the column headed “Brand” in the First and Second Schedules denote the manufacturer whose name is specified in relation to those letters in the following table:—

Letters.	Manufacturer’s Name.
AB	Abbott Laboratories Pty. Limited
AH	Allen & Hanburys (A’asia.) Ltd.
AN	Andrew’s Laboratories.
AS	Anglo Swiss Drug Company Pty. Ltd.
AD	Associated Drug Co.
BA	Bayer Pharma Pty. Ltd.
BT	Boots Pure Drug Co. (Aust.) Pty. Ltd.
BD	The British Drug Houses (Australia) Pty. Ltd.
BP	British Pharmaceuticals Pty. Ltd.
BS	British Schering Ltd.
BL	David G. Bull Laboratory
BW	Burroughs Wellcome & Co. (Australia) Ltd.
CM	Charles McDonald Pty. Ltd.
CB	Ciba Limited
CS	Commonwealth Serum Laboratories
CK	The Crookes Laboratories Limited
CO	Colonial Sugar Refining Co.
DN	Deutsche Novocillin Gesellschaft
DH	Drug Houses of Australia Ltd.
EV	Evans Medical Supplies Ltd;
FA	P. H. Paulding & Co. Limited
FM	Fawns and McAllan Pty. Ltd.
FC	Fisons Chemicals (Pty.) Limited
GA	Gamma Laboratories
GE	Geigy (Australasia) Pty. Limited
GP	G.P. Pty. Ltd.
GL	Glaxo Laboratories (Aust.) Pty. Ltd.
HA	The Hamilton Laboratories Ltd.
HY	H. P. Harvey Pty. Ltd.
HT	Herts Pharmaceuticals Ltd.
IC	Imperial Chemical Industries of Australia and New Zealand Limited
KL	Knoll Laboratories
KN	Knoll
LE	Lederle Laboratories
LY	Eli Lilly and Company
MT	W. Martindale
MB	May and Baker (Australia) Pty. Ltd.
ME	Medical Research Pty. Limited
MJ	Menley and James (Colonial) Limited
NA	Nativelle Laboratories
NS	Nicholas Proprietary Limited
NO	Nordisk Insulin Laboratorium
OX	Oxo Limited
OP	Oppenheimer, Sons & Co. Ltd.
PD	Parke, Davis and Co. Ltd.
PF	Chas. Pfizer & Co. Inc.
RO	Roche Products Ltd.
RT	Rocke Tompsitt & Co. Ltd.
RL	Roussel Laboratories Ltd.
SY	Sandoz Ltd.
SY	Savory & Moore Ltd.
SC	Schering Pty. Ltd.
SD	Sharpe & Dohme Inc.
SI	Sigma Co. Ltd.
SM	Simanite (A’asia.) Pty. Ltd.
SP	Societe Parisienne d’Expansion Chimique, S.A
Letters.			Manufacturer’s Name.
ST		Frederick Stearns & Company
TO		R. D. Toppin & Son Pty. Ltd.
VR		Virax Ethicals Pty. Ltd.
VM		Vitamins Limited
WA		A. Wander limited
WY		Wyeth International Limited
WD		Wholesale Drug Co. Ltd.
WB		Ward Blenkinsop & Co. Ltd.
WW		William R. Warner & Co. Pty. Ltd.

(3.) In these Regulations, unless the contrary intention appears, a reference to prescribing or to the writing of a prescription shall be read as a reference to the writing of a prescription for the supply of a pharmaceutical benefit under Part VII. of the Act.

(4.) A disease or purpose specified in the column headed “Disease or Purpose” in the Second Schedule applies in relation to each form of the drug or medicinal preparation in relation to which that disease or purpose is specified.

(5.) Unless the contrary intention appears, weights and measures howsoever represented or expressed in these Regulations shall be deemed to relate to the table of weights and measures known as the “Apothecaries’ Table of Weights and Measures” that appears in the twelfth revision of the United States Pharmacopoeia.

(6.) In these Regulations, a reference to a Schedule by number shall be read as a reference to the Schedule to these Regulations so numbered, and a reference to a Form by letter shall be read as a reference to the Form so lettered in the Sixth Schedule.

(7.) Strict compliance with the Forms contained in the Sixth Schedule is not necessary and substantial compliance is sufficient.

Delegation.

3.—(1.) The Director-General may, in relation to a matter or class of matters, or to a State or part of the Commonwealth, by writing under his hand, delegate any of his powers and functions under these Regulations (except this power of delegation) to a Deputy Director of Health or to an officer of the Commonwealth Department of Health who is a pharmacist.

(2.) A power or function so delegated may be exercised or performed by the delegate with respect to the matter or class of matters, or with respect to the State or part of the Commonwealth, specified in the instrument of delegation.

(3.) A delegation under this regulation is revocable at will and does not prevent the exercise of a power or the performance of a function by the Director-General.

Persons not entitled to receive pharmaceutical benefits.

4. A person who is a passenger or a member of the crew on a foreign-going ship as defined by the Navigation Act 1912-1953 is not entitled to receive a pharmaceutical benefit.

Application for approval by a pharmaceutical chemist or hospital authority.

5. The Director-General may refuse to entertain an application by a pharmaceutical chemist or a hospital authority for approval under Part VII. of the Act unless the application for approval

is on and in accordance with Form A, Form B or Form C, whichever is appropriate, or in such form as the Director-General specially permits.

Signs to be displayed by pharmaceutical chemists.

6.—(1.) An approved pharmaceutical chemist shall display a sign in accordance with Form D in a conspicuous place in or on each of the premises in respect of which he is approved in such a manner as to he readily visible to persons who enter those premises.

(2.) The last preceding sub-regulation does not apply to or in relation to a friendly society dispensary the approval of which is limited in accordance with sub-section (3.) of section 91 of the Act.

Penalty: Ten pounds.

Certain requirements to be met after cancellation, &c., of approval.

7. Where the approval of an approved pharmaceutical chemist is suspended, revoked or cancelled, the approved pharmaceutical chemist—

(a)shall, if the Director-General so requests, deliver up to the Director-General all documents and forms supplied to him by the Commonwealth with respect to the provision of pharmaceutical benefits other than documents or forms that he has parted with in accordance with Part VII. of the Act and these Regulations or the Regulations repealed by that Part; and
(b) shall not display a sign indicating that he has been, or is, approved to supply pharmaceutical benefits.

Penalty: Fifty pounds.

General pharmaceutical benefits.

8.—(1.) The drugs and medicinal preparations that may be prescribed for supply, supplied and received as general pharmaceutical benefits are those specified in the First and Second Schedules.

(2.) Except as provided by the next succeeding sub-regulation, the general pharmaceutical benefits specified in the Second Schedule may be prescribed by a medical practitioner for the purposes of Part VII. of the Act only for the treatment of a disease or for a purpose specified in that Schedule in relation to the general pharmaceutical benefit.

(3.) A medical practitioner may, in respect of a pensioner, prescribe the following drugs for the treatment of any disease from which the pensioner is suffering:—

Quinine Bisulphate.

Quinine Dihydrochloride.

Quinine Hydrochloride.

Quinine Sulphate.

(4.) Water for Injection as prescribed in the First Schedule is not a general pharmaceutical benefit unless it is prescribed for supply in conjunction with and for administration with—

(a)Injection of Penicillin as prescribed as a general pharmaceutical benefit;
(b) Injection of Procaine Penicillin (Crystalline) as prescribed as a general pharmaceutical benefit;
(c) Dihydrostreptomycin as prescribed as a general pharmaceutical benefit;

(d) Streptomycin as prescribed as a general pharmaceutical benefit; or
(e) another drug or medicinal preparation that is prescribed as a general pharmaceutical benefit in the form of a hypodermic tablet.

Exceptions to pensioner benefits in British Pharmacopoeia.

9.—(1.) The following drugs and medicinal preparations, being drugs and medicinal preparations that are the subject of monographs in the British Pharmacopoeia, are not pensioner pharmaceutical benefits:—

(a) drugs and medicinal preparations that are medicinal gases;
(b) drugs and medicinal preparations containing diamorphine hydrochloride;
(c) drugs and medicinal preparations that are prescribed as general pharmaceutical benefits by the last preceding regulation.

(2.) A drug or medicinal preparation specified in the following list is not a pensioner pharmaceutical benefit unless it is an ingredient in, a medicinal compound that contains another drug or medicinal preparation that is a pensioner pharmaceutical benefit:—

Aether Anaestheticus.

Aether Vinylicus.

Aethylis Chloridum.

Alcohol.

Alcohol Tribromoethylicum.

Amyleni Hydras.

Bromethol.

Chloroformum.

Cyclopropanum.

Spiritus Methylatus Industrialis.

Thiopentonum Sodium.

Trichloroaethvlenum.

Benefits available to pensioners.

10. A drug or medicinal preparation specified in the Third Schedule is a drug or medicinal preparation available to pensioners if the drug or medicinal preparation—

(a) is in the form of a cachet, capsule, cream, eye ointment, extract, glycerine, injection, linament, liquor, mixture, ointment, pill, suppository, syrup or tablet indicated in that Schedule in the name or formula of that drug or medicinal preparation; or
(b) is an ingredient in a medicinal compound that contains another drug or medicinal preparation that is a pensioner pharmaceutical benefit.

Forms of pensioner pharmaceutical benefits.

11. A drug or medicinal preparation prescribed for supply in the form of a cachet, capsule, pill or tablet is not a pensioner pharmaceutical benefit unless the form in which it is prescribed for supply is a form specified in relation to that drug or medicinal preparation in the Third Schedule or in a monograph in the British Pharmacopoeia.

Maximum quantity or number of units of pharmaceutical benefits.

12.—(1.) The maximum quantity or number of units of a general pharmaceutical benefit that may be prescribed for supply at any one time is the quantity or number of units specified in the First or the Second Schedule, as the case may be.

(2.) The maximum quantity or number of units of a pensioner pharmaceutical benefit that may be prescribed for supply at any one time is, in respect of a form specified in the Fourth Schedule, such quantity or number of units as is specified in relation to that form in that Schedule.

Pharmaceutical benefits that may be supplied under section 93.

13.—(1.) The pharmaceutical benefits that a medical practitioner is authorized to supply for the purpose of section 93 of the Act are the general pharmaceutical benefits the names or formulae of which are specified in the Fifth Schedule and, subject to these Regulations, he may obtain those pharmaceutical benefits in the forms and quantities specified in that Schedule.

(2.) Where more than one form of a unit is specified in the Fifth Schedule, the maximum quantity or number of units of each of the forms so specified may be obtained by a medical practitioner under this regulation.

(3.) Where in the First Schedule more than one strength is specified in relation to a form of a drug or medicinal preparation that is specified in the Fifth Schedule, a medical practitioner may, for the purpose of section 93 of the Act, obtain that form of the drug or medicinal preparation in all or any of those strengths if the quantity or number of units of each strength obtained by the medical practitioner is the quantity or number of units contained in a standard package.

(4.) The last preceding sub-regulation does not entitle a medical practitioner to obtain a total quantity or number of units of more than one strength of a particular form of a drug or medicinal preparation that exceeds the maximum quantity or number of units specified in relation to that form in the Fifth Schedule.

(5.) In this regulation “standard package” means a package containing such quantity or number of units as the Director-General determines in relation to a specified product of a specified manufacturer.

Medical practitioners excepted from the authorization conferred by section 93.

14. A medical practitioner who is an approved medical practitioner and a medical practitioner who is practising his profession on a ship are not authorized to supply pharmaceutical benefits under section 93 of the Act.

Obtaining of drugs by medical practitioners for purpose of section 93.

15.—(1.) A medical practitioner shall not obtain a drug or medicinal preparation for the purpose of section 93 of the Act by any means other than by signing and lodging with an approved pharmaceutical chemist an order, in duplicate, on and in accordance with the authorized form.

(2.) A medical practitioner is not entitled to obtain a pharmaceutical benefit for the purpose of section 93 of the Act more often than once in any one month.

(3.) Where a medical practitioner has obtained a pharmaceutical benefit in accordance with this regulation, he is not entitled to obtain any further supply of that pharmaceutical benefit while he has in his possession a quantity or number of units of that pharmaceutical benefit equal to or greater than the maximum quantity or number of units allowable under regulation 13 of these Regulations.

Supply of pharmaceutical benefits by chemists for purpose of section 93.

16. An approved pharmaceutical chemist shall not supply a pharmaceutical benefit on an order given under the last preceding regulation unless the medical practitioner whose signature appears on the order is known to him or, if the medical practitioner is not known to him, he obtains from the person who presents the order particulars of the full name, address and medical registration number of the medical practitioner and endorses those particulars on the back of the order form.

Penalty: Twenty pounds.

Supply of particular brand for purpose of section 93.

17. Where a medical practitioner specifies in an order given under regulation 15 of these Regulations a particular brand of a pharmaceutical benefit specified in the Fifth Schedule, an approved pharmaceutical chemist shall supply that brand of the pharmaceutical benefit.

Penalty: Fifty pounds.

Payment for pharmaceutical benefits supplied for the purpose of section 93.

18. An approved pharmaceutical chemist who has supplied a pharmaceutical benefit to a medical practitioner for the purpose of section 93 of the Act in accordance with these Regulations is entitled to payment from the Commonwealth in respect of the supply of that pharmaceutical benefit at such rate and subject to such conditions as are determined by the Minister and applicable at the time of the supply.

Writing of prescriptions.

19.—(1.) A prescription is not duly written unless the medical practitioner who writes the prescription—

(a) writes the prescription in his own handwriting, unless the Director-General otherwise allows, on an authorized prescription form;
(b) writes the prescription in duplicate and marks that duplicate with the word “Duplicate”;
(c) dates and signs the prescription;
(d) states the name and address of the person for whom the pharmaceutical benefit is to be supplied;
(e) where the prescription is for the supply of a general pharmaceutical benefit—identifies that benefit by its name as specified in the First or the Second Schedule or by the trade name of a manufacturer an abbreviation of whose name appears in the column headed “Brand” in that Schedule;
(f) where the prescription is for the supply of a pensioner pharmaceutical benefit—
(i) states the pension number of the pensioner to whom the pensioner pharmaceutical benefit is to be supplied; and
(ii) if the benefit to be supplied consists of a single drug, indicates the mode in which the benefit is to be used; and
(g) where the prescription is for the supply of a general pharmaceutical benefit specified in the Second Schedule—endorses the prescription in his own handwriting with the words “Restricted Drug”.

(2.) A prescription is not duly written if the prescription—

(a)prescribes a general pharmaceutical benefit and a pensioner pharmaceutical benefit;
(b) includes two prescriptions for the same pharmaceutical benefit;

(c) prescribes pharmaceutical benefits for more than one person;
(d) prescribes more than two general pharmaceutical benefits or more than two pensioner pharmaceutical benefits;
(e) prescribes a pensioner pharmaceutical benefit by reference to a brand or in any other manner that indicates a brand; or
(f) prescribes for the supply to a person of a pharmaceutical benefit for the supply of which to the same person another prescription has been written by the same medical practitioner on the same day.

(3.) For the purposes of paragraph (d)of the last preceding sub-regulation, a prescription for the supply as a general pharmaceutical benefit of two or more strengths of a form of one of the following drugs or medicinal preparations shall be deemed to prescribe one general pharmaceutical benefit:—

Oily Injection of Aurothioglucose.

Injection of Calcium Aurothiomalate.

Pertussis Vaccine (Phase 1).

Aqueous Injection of Sodium Aurothiomalate.

Oily Injection of Sodium Aurothiomalate.

(4.) A prescription for Cortisone Acetate shall be deemed not to be duly written—

(a) unless the medical practitioner who writes the prescription has applied to the Director-General in accordance with Form E for authority to write such a prescription and that authority has been given on a form issued and numbered by the Director-General; or
(b) if he writes another prescription on the same authorized prescription form as that on which he prescribes Cortisone Acetate.

Repeat prescriptions.

20.—(1.) Subject to these Regulations, a medical practitioner may, in a prescription, direct that the supply of a pharmaceutical benefit be repeated a specified number of times not exceeding—

(a) in the case of a general pharmaceutical benefit—the number specified in the First or the Second Schedule in relation to that benefit; or
(b) in the case of a pensioner pharmaceutical benefit—such number as is determined by the Director-General in respect of the pensioner pharmaceutical benefit in the form specified in the prescription.

(2.) The last preceding sub-regulation does not entitle a medical practitioner to direct a repeat unless—

(a)in the case of a general pharmaceutical benefit—the quantity or number of units that he directs to be supplied on the first occasion is the maximum quantity or number of units specified in relation to that benefit in the First or the Second Schedule; or
(b) in the case of a pensioner pharmaceutical benefit in respect of which a maximum quantity or number of units is specified in the Fourth Schedule—the quantity or number of units that he directs to be supplied on the first occasion is that maximum.

Prescription of dangerous drugs.

21.—(1.) A prescription for the supply of a dangerous drug as a pharmaceutical benefit is not duly written if the medical practitioner who writes the prescription writes a prescription for another pharmaceutical benefit on the same authorized prescription form as that on which he prescribes the dangerous drug and he directs that one of those pharmaceutical benefits is to be supplied more than once.

(2.) In this regulation, “dangerous drug” means a drug or medicinal preparation in respect of which the law of the State or Territory in which the prescription is written provides that a pharmaceutical chemist who dispenses that drug or medicinal preparation or who dispenses it on the last of a number of occasions of supply indicated in a prescription for its supply, shall take possession of the prescription and cancel it or deliver it to the authority administering that law.

Recovery of cost of pharmaceutical benefits prescribed in excessive quantities.

22. If a Committee of Inquiry established under Division 2 of Part VIII. of the Act reports that, in its opinion, a medical practitioner has prescribed a quantity or number of units of a pharmaceutical benefit that is greater than the quantity or number of units of that pharmaceutical benefit that could reasonably be necessary for the proper medical treatment of the person in respect of whose medical treatment the prescription was written, the medical practitioner is liable to repay to the Commonwealth the amount of the cost to the Commonwealth of the excess quantity or number of units of the pharmaceutical benefit supplied on the prescription and that amount is recoverable as a debt due to the Commonwealth.

Supply of pharmaceutical benefits on prescriptions.

23.—(1.) An approved pharmaceutical chemist, an approved medical practitioner or an approved hospital authority (being the proprietor of a private hospital) is not authorized to supply a drug or medicinal preparation as a pharmaceutical benefit unless—

(a)subject to the next succeeding regulation, the prescription for its supply is surrendered to him;
(b) the prescription for its supply is duly written in accordance with these Regulations and is accompanied by a duplicate of the prescription on an authorized prescription form;
(c) where the prescription is for the supply of a pensioner pharmaceutical benefit—the entitlement card issued to the pensioner to whom the pensioner pharmaceutical benefit is to be supplied is produced; and
(d) the prescription for its supply is dated within six months before the date of its presentation.

(2.) An approved pharmaceutical chemist, an approved hospital authority or an approved medical practitioner is not authorized to supply Cortisone Acetate as a pharmaceutical benefit unless the prescription for its supply is accompanied by a numbered authority given under sub-regulation (4.) of regulation 19 of these Regulations.

Supply of pharmaceutical benefit before surrender of written prescription.

24.—(1.) A pharmaceutical benefit may be supplied by an approved pharmaceutical chemist or an approved hospital authority before the prescription for that pharmaceutical benefit is surrendered to him where, in a case of urgency, a medical practitioner, by oral or other means, communicates the prescription to the approved pharmaceutical chemist or approved hospital authority.

(2.) A medical practitioner who has communicated a prescription in the manner referred to in the last preceding sub-regulation shall reduce the communicated prescription to writing in accordance with regulation 19 of these Regulations and within twenty-four hours of the communication despatch the prescription so written to the approved pharmaceutical chemist or approved hospital authority who supplied the pharmaceutical benefit.

Penalty: Ten pounds.

(3.) This regulation does not apply to the following pharmaceutical benefits:—

Cortisone Acetate.

A pharmaceutical benefit that is a drug or medicinal preparation the prescription for which is required to be in writing by or under a law of the State or Territory of the Commonwealth in which the premises of the approved pharmaceutical chemist or approved hospital authority are situated.

(4.) In this regulation, “approved hospital authority” means a proprietor of a private hospital who is an approved hospital authority.

Supply of pharmaceutical benefit on first presentation of prescription.

25. An approved pharmaceutical chemist, approved medical practitioner or approved hospital authority (being the proprietor of a private hospital) is not authorized to supply a pharmaceutical benefit on the first presentation of a prescription unless—

(a) he writes on the back of the authorized prescription form and on the back of the duplicate his name and the number of his approval (if any) under the Act;
(b) if two pharmaceutical benefits have been prescribed on the authorized prescription form—he marks on that form and on the duplicate the first-written pharmaceutical benefit with the letter “A” and the other pharmaceutical benefit with the letter “B” and initials that marking; and
(c) in the case of an approved pharmaceutical chemist—he allots a serial number to the prescription and writes that serial number on the authorized prescription form and on the duplicate.

Supply of repeats.

26.—(1.) A pharmaceutical benefit shall not be supplied a number of times greater than the number specified, in accordance with regulation 20 or regulation 27 of these Regulations, in the prescription.

(2.) Where a prescription directs that a pharmaceutical benefit is to be supplied more than once, that benefit shall not be supplied (whether by the same supplier or by different suppliers) more than once on the same day.

Penalty: Ten pounds.

Special approval for repeats.

27. In special circumstances the Director-General may authorize, subject to such conditions as he determines, a pharmaceutical benefit to be prescribed by a medical practitioner and to be supplied a number of times greater than the number of times otherwise allowed by regulation 20 of these Regulations.

Repeat authorizations.

28.—(1.) An approved pharmaceutical chemist who supplies a pharmaceutical benefit on surrender of—

(a) a prescription that contains a direction to supply that benefit more than once; or
(b) a repeat authorization issued in accordance with this regulation,

shall, unless no further supply of the pharmaceutical benefit (after the supply that he is making) is authorized—

(c) issue, to the person presenting the prescription or repeat authorization, a repeat authorization, on and in accordance with an authorized form, in respect of each benefit the further supply of which is authorized;
(d) write the repeat authorization in duplicate and mark that duplicate with the word “Duplicate”;
(e) attach the repeat authorization to the duplicate of the prescription;
(f) in the case of the supply of a pharmaceutical benefit on the first occasion—mark on the repeat authorization the number of his approval under the Act and the serial number allotted by him to the prescription; or
(g) in the case of the supply of a pharmaceutical benefit on a subsequent occasion—mark on the repeat authorization that he issues the numbers marked, in pursuance of the last preceding sub-paragraph, on the repeat authorization presented to him.

(2.) A pharmaceutical benefit shall not be supplied upon surrender of the duplicate of a prescription unless—

(a) there is attached to that duplicate a repeat authorization—

(i) duly related to the duplicate prescription by a number or numbers;

(ii) where the prescription refers to two pharmaceutical benefits—referring to the first-written pharmaceutical benefit by the letter “A” and the second-written pharmaceutical benefit by the letter “B”; and
(iii) indicating that the pharmaceutical benefit to be supplied has not been supplied for the number of times directed in the prescription; and
(b)the person obtaining the pharmaceutical benefit surrenders the repeat authorization to the person supplying the pharmaceutical benefit.

(3.) An approved pharmaceutical chemist who supplies a benefit on presentation of a repeat authorization shall write his name on the back of the repeat authorization.

Penalty: Ten pounds.

Supply of brand of general pharmaceutical benefit specified in a prescription.

29. Where a prescription for the supply of a general pharmaceutical benefit, presented to an approved pharmaceutical chemist, approved hospital authority or approved medical practitioner, indicates a brand of that general pharmaceutical benefit, the approved pharmaceutical chemist, approved hospital authority or approved medical practitioner, as the case may be, shall not supply any other brand of that general pharmaceutical benefit unless the Director-General otherwise allows.

Penalty: Fifty pounds.

Receipts.

30.—(1.) Subject to this regulation, upon the supply to a person of a pharmaceutical benefit by an approved pharmaceutical chemist or an approved medical practitioner, that person shall sign and date a receipt for that pharmaceutical benefit and, if that person is not the person for whose treatment the prescription was written, that person shall write on the back of the authorized prescription form or repeat

authorization form, as the case may be, his address and a statement that he is obtaining the benefit for and on behalf of the person for whose treatment the prescription was written.

(2.) An approved pharmaceutical chemist or an approved medical practitioner shall not demand a receipt for the supply of a pharmaceutical benefit to a person unless the approved pharmaceutical chemist or approved medical practitioner has supplied that pharmaceutical benefit to that person.

(3.) Where a pharmaceutical benefit is supplied by an approved pharmaceutical chemist or an approved medical practitioner through the post or by rail or other means of transport and it is impracticable for him to obtain a receipt in accordance with the preceding provisions of this regulation, the approved pharmaceutical chemist or approved medical practitioner shall certify on the back of the authorized prescription form or repeat authorization form that he has supplied the pharmaceutical benefit, stating the date on which the supply was made and also particulars of the means by which the pharmaceutical benefit was supplied.

Penalty: Twenty pounds.

Presentation of prescriptions in trading hours.

31.—(1.) An approved pharmaceutical chemist shall, at all times, keep prominently displayed at each of the premises in respect of which he is approved, so as to be readily visible to persons who enter each premises, a notice in an authorized form setting out the trading hours during which services for the supply of pharmaceutical benefits are available.

(2.) Subject to the next succeeding regulation, a person is entitled on demand to be supplied with a pharmaceutical benefit from an approved pharmaceutical chemist only during trading hours.

Presentation of urgent prescriptions.

32.—(1.) A prescription for the supply of a pharmaceutical benefit marked “Urgent”, that marking being initialled by the medical practitioner writing the prescription, may be presented at any time to an approved pharmaceutical chemist at the premises in respect of which he is approved.

(2.) Subject to the next succeeding sub-regulation, where a prescription referred to in the last preceding sub-regulation is so presented, the approved pharmaceutical chemist shall, as soon as practicable, supply the pharmaceutical benefit.

Penalty: Ten pounds.

(3.) An approved pharmaceutical chemist may refuse to supply a pharmaceutical benefit outside trading hours unless a special charge is paid in accordance with the next succeeding regulation.

Special charges for supply outside trading hours.

33.—(1.) An approved pharmaceutical chemist is entitled to make a special charge of such amount as is determined by the Director General in respect of the supply of a pharmaceutical benefit outside trading hours.

(2.) Where two or more prescriptions are presented to an approved pharmaceutical chemist at the same time, being outside trading hours, for the supply of pharmaceutical benefits to the same person, the approved pharmaceutical chemist is entitled to make one special charge only.

Special charge for delivery.

34. When a pharmaceutical benefit is supplied by delivery at or to a place other than premises in respect of which the approved pharmaceutical chemist is approved, the premises at which an approved medical

practitioner carries on his practice or the hospital in respect of which an approved hospital authority is approved, as the case may he, the pharmaceutical chemist, medical practitioner or hospital authority is entitled to make a special charge equal to the cost of delivery and to refuse to deliver the pharmaceutical benefit unless the special charge is paid by or on behalf of the person to whom the pharmaceutical benefit is to he supplied.

Retention of prescriptions, &c.

35. Subject to regulation 21 of these Regulations, an approved pharmaceutical chemist, approved medical practitioner or approved hospital authority (being the proprietor of a private hospital) who or which supplies pharmaceutical benefits shall retain in his or its possession for a period of not less than twelve months from the respective dates on which prescriptions for the supply of the pharmaceutical benefits were written—

(a)in the case of prescriptions that do not bear instructions to supply pharmaceutical benefits more than once—the duplicates of those prescriptions;
(b) in the case of prescriptions that bear instructions to supply pharmaceutical benefits more than once—the duplicates of repeat authorizations issued in accordance with regulation 28 of these Regulations;
(c) where the pharmaceutical benefits are supplied on the last occasion on which supply is authorized—the duplicates of the prescriptions in respect of which repeat authorizations were issued; and
(d) the duplicates of order forms lodged under regulation 15 of these Regulations.

Penalty: Fifty pounds.

Proper stocks to be kept.

36. An approved pharmaceutical chemist shall, as far as practicable, keep in stock an adequate supply of all drugs and medicinal preparations that he may reasonably be expected to be called upon to supply as pharmaceutical benefits or as ingredients of pharmaceutical benefits.

Penalty: Ten pounds.

Forms suspected forged, &c.

37. Where an approved pharmaceutical chemist suspects that a prescription has not been signed by a medical practitioner or has been forged or fraudulently obtained, he is entitled, before supplying the pharmaceutical benefit specified in the prescription, to require that there be furnished to him a statement in accordance with an authorized form.

Standards of composition and purity of pharmaceutical benefits.

38.—(1.) The standards of composition and purity of drugs and medicinal preparations that may be supplied as pharmaceutical benefits or may be ingredients of pharmaceutical benefits are as prescribed by this regulation.

(2.) A drug or medicinal preparation that is a general pharmaceutical benefit specified in the First or the Second Schedule shall conform to such standards of composition and purity as are specified in relation to that drug or medicinal preparation in the British Pharmacopoeia, the British Pharmaceutical Codex or the Australian Pharmaceutical Formulary, as the case may be.

(3.) A drug or medicinal preparation that is a pensioner pharmaceutical benefit referred to in sub-paragraph (i) of paragraph (b)of sub-section (1.) of section 85 of the Act shall conform to the standards

of composition and purity constituted by the statements in the monograph in the British Pharmacopoeia relating to that drug or medicinal preparation.

(4.) A drug or medicinal preparation that is a pensioner pharmaceutical benefit specified in the Third Schedule shall—

(a) where the letters “A.P.F.” appear after the name or formula of the drug or medicinal preparation—conform to the standards of composition and purity constituted by the description of that drug or medicinal preparation in the Australian Pharmaceutical Formulary;
(b) where the letters “B.P.C.” appear after the name or formula of the drug or medicinal preparation—conform to the standards of composition and purity constituted by the statements in the monograph relating to that drug or medicinal preparation in the British Pharmaceutical Codex; and
(c) where no letters appear after the name or formula of the drug or medicinal preparation—conform to the standards of composition and purity constituted by the statements in the monograph relating to that drug or medicinal preparation in the British Pharmacopoeia (1948).

Samples.

39. When a sample of a drug, medicine or substance that may be supplied as, or may be an ingredient of, a pharmaceutical benefit is taken in pursuance of the power conferred upon an authorized person by section 104 of the Act and that sample conforms to the standards of composition and purity prescribed by the last preceding regulation, payment shall be made by the Commonwealth as if the quantity of the drug, medicine or substance taken as a sample had been supplied as a pharmaceutical benefit.

Entitlement cards.

40. For the purposes of paragraph (e) of sub-section (1.) of section 104 of the Act and paragraph (c) of sub-regulation (1.) of regulation 23 of these Regulations, an authorized person may, in his own name or in a fictitious name, present an entitlement card purporting to have been issued to a pensioner.

Surrender of forms.

41.—(1.) The Director-General may, by notice in writing served on a person, require that person to surrender to the Director-General or to a person specified in the notice, within a time specified in the notice, any unused forms that have been supplied to that person by or on behalf of the Commonwealth under or for the purposes of the Act or these Regulations and that are in the possession of the person.

(2.) A person upon whom a notice given in pursuance of the last preceding sub-regulation is served shall comply with that notice.

Penalty: Ten pounds.

Use of old forms.

42. Where the Commonwealth supplies or has supplied a form that is substantially in accordance with a form prescribed by these Regulations or an authorized form, except that it bears a reference or references to the Pharmaceutical Benefits Act 1947-1949, that form may be used for the purposes of these Regulations as if it were in accordance with the prescribed form or the authorized form, as the case may be, to which it substantially corresponds, and these Regulations apply in relation to that form as if it were in accordance with that prescribed form or that authorized form.

THE SCHEDULES.

FIRST SCHEDULE. Reg. 8.

Drugs and Medicinal Preparations that may be Prescribed for Supply, Supplied and Received as General Pharmaceutical Benefits.

Item Number.	Name or Formula	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
1	Acetarsol Soluble, Injection of	..................................................	2 cc. amp...................................	MB ...........................................	10	1
..................................................	3 cc. amp...................................	MB ........................................... .	10	1
2	Adrenalin Hydrochloride,	1 in 1,000 ..................................	0.5 cc. amp................................	DH, PD .....................................	6	1
Solution of	1 in 1,000 ..................................	1 cc. amp...................................	DH, KL, PD ..............................	6	1
1 in 1,000 ..................................	10 cc. vial..................................	FA, PD .....................................	1	1
1 in 1,000 ..................................	1 fl. oz. bottle ...........................	DH, RT .....................................	1	..
1 in 1,000...................................	1 fl. oz. vial ..............................	DH, FA, KL, PD, RT .................	1	..
1 in 100 .....................................	6 cc. vial ...................................	PD ............................................	1	1
1 in 100 .....................................	10 cc. vial .................................	DH, FA..................................... .................................................	1
3	Adrenalin in Oil, Injection of	2 mg. per cc................................	1 cc. amp...................................	AH, DH, PD .............................	6	1
4	Adrenalin Tartrate, Solution of	1 in 1,000 ..................................	1 cc, amp...................................	AH, BL, BW, DH	6	1
1 in 1,000 ..................................	10 cc. amp.................................	BW ...........................................	1	1
1 in 1,000 ..................................	25 cc. bottle ..............................	BW ........................................... .	1	..
1 in 1,000 ..................................	30 cc. vial .................................	BT ............................................	1	..
1 in 1,000 ..................................	1 fl. oz. bottle ........................... .	AH ...........................................	1	..
1 in 100 .....................................	7 cc. vial ...................................	BW ...........................................	1	1
5	Aloxidone ..................................	0.3 G..........................................	capsule .....................................	BS ............................................ .	100	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
6	Amidone ...................................	5 mg. per cc................................	2 cc. amp...................................	BA ...........................................	6	..
5 mg. per cc................................	10 cc. vial ..................................	BA ...........................................	1	..
10 mg. per cc..............................	1 cc. amp...................................	BW, CM ..................................	6	..
10 mg. per cc..............................	10 cc. vial ..................................	CM ..........................................	1	..
10 mg. per cc..............................	20 cc. vial ..................................	BA ...........................................	1	..
2.5 mg........................................	tablet .........................................	BA ...........................................	25	..
5 mg...........................................	tablet .........................................	BA, BW, CM, ST .....................	25	..
7.5 mg........................................	tablet .........................................	BA ...........................................	25	..
10 mg.........................................	tablet .........................................	BA ...........................................	25	..
7	Amyl Nitrite ...........................	2 min..........................................	capsule ......................................	DH ...........................................	12	1
3 min..........................................	capsule ...................................... ..................................................	AH, DH ...................................	12	1
4 min..........................................	capsule ......................................	AH, DH ...................................	12	1
5 min..........................................	capsule ...................................... ..................................................	AH, DH ...................................	12	1
8	Anahaemin ..............................	..................................................	2 cc. amp...................................	BD ...........................................	12	1
9	Anahepol .................................	..................................................	2 cc. amp...................................	AH ...........................................	12	1
10	Antazoline, Injection of ........	0.1 G. per 2 cc............................	2 cc. amp. ..................................	BT, CB .....................................	10	..
11	Atropine Sulphate ..................	1/150 gr. per cc...........................	1 cc. amp. ..................................	AH, BL, DH, KL.......................	6	1
1/100 gr. per cc...........................	1 cc. amp...................................	AH, BL, BT, DH, KL................	6	1
1/100 gr. per cc...........................	10 cc. vial ..................................	FA ...........................................	1	..
1/50 gr. per cc.............................	1 cc. amp...................................	BL, DH, KL .............................	6	1
1/200 gr .....................................	hypo. tab. ..................................	BW, HY, PD ............................	20	1
1/150 gr .....................................	hypo. tab....................................	BT, BW, DH, FA, HY, PD.........	20	1
1/100 gr .....................................	hypo. tab....................................	BT, BW, DH, FA, HY, PD.........	20	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
12	Aurothiglucose, Oily	0.01 G. .....................................	amp.................................................	SC ...........................................	1	3
Injection of	0.025 G....................................	amp.................................................	SC ...........................................	1	3
0.05 G. .....................................	amp. .................................................	SC ...........................................	6	..
0.1 G. .......................................	amp. .................................................	SC ...........................................	6	..
0.01 G. per cc. ..........................	10 cc. vial .................................................	SC ...........................................	1	..
0.1 G. per cc. ............................	10 cc. vial .................................................	SC ...........................................	1	..
13	Benzhexol Hydrochloride	2 mg. ........................................	tablet .................................................	LE, ST .....................................	100	1
5 mg. ........................................	tablet .................................................	LE ...........................................	100	1
14	Bismuth, Aqueous Injection of	.................................................	5 cc. amp.................................................	BT ...........................................	2	..
................................................	10 cc. amp. .................................................	BT ...........................................	1	..
.................................................	25 cc. bottle .................................................	BW, MB...................................	1	..
................................................	1 fl. oz. bottle ..................................................	BT ...........................................	1	..
15	Bismuth Oxychloride, Aqueous	................................................	1 cc. amp.................................................	BD, BT ....................................	12	..
Injection of	................................................	2 cc. amp. .................................................	BD ...........................................	12	..
................................................	3 cc. amp..................................................	BD ...........................................	12	..
................................................	25 cc. bottle .................................................	BW ..........................................	1	..
................................................	30 cc. bottle .................................................	BD, EV ....................................	1	..
16	Bismuth Oxychloride, Oily	.................................................	2 cc. amp. .................................................	DH ...........................................	12	..
Injection of	................................................	3 cc. amp. .................................................	DH ...........................................	12	..
17	Bismuth Salicylate, Oily	.................................................	1 cc. amp. .................................................	AH, DH, KL .............................	12	..
Injection of	.................................................	10 cc. amp. .................................................	DH, KL ....................................	6	..
................................................	25 cc. bottle	EV, KL ....................................	1	..
.................................................	50 cc. bottle	MB ..........................................	1	..
.................................................	60 cc. bottle .................................................	DH, KL ....................................	1	..
................................................	2 fl. oz. bottle .................................................	PD ...........................................	1	..

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
18	Calcium Aurothiomalate,	10 mg........................................	amp. .........................................	CK ...........................................	1	3
Injection of	25 mg........................................	amp. .........................................	CK ...........................................	1	3
50 mg........................................	amp..........................................	CK ...........................................	6	..
100 mg......................................	amp..........................................	CK ...........................................	6	..
19	Calf Lymph..................................	.................................................	capillary tube ............................	CS ............................................	1	..
20	Camoquin Hydrochloride.........	0.2 G. .......................................	tablet ........................................	PD ............................................	25	..
21	Campolon....................................	.................................................	2 cc. amp..................................	BA ...........................................	5	1
................................................	5 cc. amp..................................	BA ...........................................	6	1
................................................	10 cc. vial .................................	BA ...........................................	1	1
22	Campolon Forte..........................	................................................	1 cc. amp..................................	BA ...........................................	6	1
................................................	5 cc. vial ...................................	BA ...........................................	1	1
................................................	10 cc. vial .................................	BA ...........................................	1	1
23	Carbachol...................................	0.25 mg. per cc..........................	1 cc. amp..................................	AH, SY ....................................	6	..
2 mg. ........................................	tablet ........................................	BD, HY, MB, SY ......................	25	3
24	Carbarsone.................................	0.25 G. .....................................	capsule .....................................	LY ...........................................	20	1
0.25 G. .....................................	tablet ........................................	BW, HY, MB ............................	20	1
25	Casydrol.....................................	2½% .. ......................................	500 cc. bottle ............................	FC ............................................	1	..
5% ........................................... .	500 cc. bottle ............................	FC ............................................	1	..
26	Chiniofon.....................................	0.25 G.......................................	pill ...........................................	BA ...........................................	25	1
0.25 G. .....................................	tablet ........................................	HY, IC .....................................	25	1
0.5 G .. .....................................	tablet ........................................	IC .............................................	25	1
27	Chloroquine................................	0.2 G .. .....................................	tablet ........................................	MB ..........................................	100	1
250 mg......................................	tablet ........................................	AN, BA ....................................	100	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
28	Cholera Vaccine .....................	4,000 M. per cc.........................	1 cc. amp..................................	CS ................................................	3	..
4,000 M. per cc. ........................	10 cc. vial .................................	CS ................................................	1	..
8,000 M. per cc. ........................	1 cc. amp. .................................	CS ................................................	2	..
8,000 M. per cc. ........................	10 cc. vial .................................	CS ................................................	1	..
29	Dapsone ...................................	50 mg. ......................................	tablet ........................................	AN ................................................	100	..
100 mg. ....................................	tablet ........................................	IC ................................................	100	..
30	Darrow’s Solution ..................	................................................	1 litre bottle ..............................	DH ................................................	2	1
31	Dextrose, Aqueous Injection of	5% ...........................................	1 litre bottle ..............................	DH ................................................	6	1
10% .........................................	1 litre bottle ..............................	DH ................................................	2	1
20% .........................................	1 litre bottle ..............................	DH ................................................	2	1
25% .........................................	1 litre bottle ..............................	DH ................................................	2	1
50% .........................................	25 cc. amp................................	DH ................................................	6	1
50% .........................................	50 cc. amp................................	DH, PD ................................................	6	1
32	Dextrose in 1/5 Normal Saline for Injection	4% ...........................................	1 litre bottle ..............................	DH ................................................	6	1
33	Dextrose in Ringer’s Solution	5% ...........................................	1 litre bottle ..............................	DH ................................................	6	1
for Injection	10% .........................................	1 litre bottle ..............................	DH ................................................	3	1
34	Diasone ....................................	0.33 G. .....................................	tablet ........................................	PD ................................................	200	1
35	Dicoumarol ..............................	100 mg. ....................................	amp. .........................................	OR .................................................	3	..
50 mg........................................	capsule .. ..................................	AB, LY ................................................	50	1
100 mg. ....................................	capsule .. ..................................	AB, LY ................................................	50	1
50 mg. ......................................	tablet ........................................	OR ................................................	50	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
36	Diethazine Hydrochloride	0.05 G.......................................	tablet ........................................	MB ..........................................	100	1
0.25 G.......................................	tablet ........................................	MB ..........................................	100	1
37	Diethylcarbamazine	50 mg........................................	tablet ........................................	BD, BW, LB .............................	20	1
38	Digifortis	1/2 gr ........................................	tablet ........................................	PD ............................................	50	1
1 gr. .........................................	tablet ........................................	PD ............................................	50	1
39	Digitalis .................................	1/2 gr ........................................	tablet ........................................	BW, DH, FA, HY, RT, SI...........	100	1
1 gr. .........................................	tablet ........................................	BW, DH, FA, HY, RT, SI...........	100	1
40	Digitoxin ................................	1/100 gr....................................	hypo. tab. .................................	BW ..........................................	20	1
0.1 mg. .....................................	tablet ........................................	BW, CM, KL, NA, SI, ST, WY...	100	1
0.2 mg.......................................	tablet ........................................ .	CM, LY, ST, WY .. ...................	100	1
0.25 mg.....................................	tablet ........................................	KL ...........................................	100	1
41	Digoxin ................................... ..	0.5 mg. per cc. ..........................	1 cc. amp. .................................	BW ..........................................	12	1
0.5 mg. per cc. ..........................	30 cc. bottle ..............................	BW ..........................................	1	1
0.25 mg.....................................	tablet ........................................	BW ..........................................	100	1
42	Dihydroergotamine, injection of	1 mg. per cc...............................	1 cc. amp. .................................	SZ .. ................................................. ..	6	..
43	Dihydromorphinone .............	................................................	1.1 cc. amp. ..............................	KN ...........................................	4	..
1/32 gr......................................	hypo. tab. ................................. .	KN ...........................................	20	..
1/20 gr ......................................	hypo. tab. .................................	KN ...........................................	20	..
1/25 gr ......................................	tablet ........................................	KN ...........................................	20	..

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
44	Diiodohydroxyquinoline ..	0.21 G.......................................	tablet ........................................	SY .................................................	100	1
0.3 G. .......................................	tablet ........................................	MB .................................................	100	1
45	Dimercaprol, Injection of ..	................................................	2 cc. amp..................................	BT .................................................	12	..
46	Diphenhydramine Hydro-chloride, Injection of	10 mg. per cc. ...........................	10 cc. vial .................................	PD .................................................	1	1
47	Diphtheria and tetanus Toxoids	................................................	1 cc. amp..................................	CS .................................................	3	..
Combined	.................................................	5 cc. amp..................................	CS .................................................	1	..
48	Diphtheria Antitoxin ..	1,000 U. ...................................	amp. .........................................	CS .................................................	2	1
2,000 U. ...................................	amp. .........................................	BW, CS .................................................	2	1
4,000 U. ...................................	amp. .........................................	BW, CS .................................................	2	1
6,000 U. ...................................	amp. .. ......................................	CS .................................................	2	1
8,000 U.....................................	amp. .........................................	BW, CS .................................................	2	1
10,000 U. .................................	amp. .........................................	BW, CS .................................................	2	1
20,000 U. .................................	amp. .........................................	BW, CS .................................................	2	1
49	Diphtheria Pertussis Antigen	.................................................	1 cc. amp..................................	CS, GL .................................................	3	..
.................................................	5 cc. amp..................................	CS .................................................	1	..
.................................................	5 cc. vial ...................................	GL .................................................	1	..
.................................................	7.5 cc. vial ................................	PD .................................................	1	..
.................................................	10 cc. vial .................................	GL .................................................	1	..
50	Diphtheria, Pertussis and..	.................................................	1 cc. amp. .................................	BW, CS, GL ................................................. .	3	..
Tetanus Antigen	.................................................	5 cc. amp. .................................	CS .................................................	1	..
.................................................	7.5 cc. vial ................................	PD, SD .................................................	1	..
.................................................	10 cc. vial .................................	BW, GL .................................................	1	..

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
51	Diphtheria Prophylactic (Formalinized Toxiod)....................	.................................................	set containing 3 amps, each 1 cc. Toxiod undiluted and 1 amp. of 1 cc. Toxoid diluted	CS ................................................	1	1
.................................................	set containing 9 amps each 1 cc. Toxoid undiluted and 3 amps of 1 cc. Toxoid diluted	CS ................................................	1	..
52	Diphtheria Prophylactic	.................................................	1 cc. amp..................................	CS ................................................	2	1
(Purified Toxoid Aluminium Phosphate)	.................................................	5 cc. vial ...................................	CS, GL ................................................	1	..
.................................................	10 cc. vial .................................	PD ................................................	1	..
.................................................	set containing 2 amps, each 1 cc. Toxoid for use in adults and 1 amp. of 1 cc. Toxoid diluted for skin test	CS ................................................	1	..
53	Diphtheria Toxoid Purified (Diluted for skin test only)	.................................................	1 cc. amp..................................	CS................................................	1	..
54	Emetine Hydrochloride ............	20 mg. per cc. ...........................	1 cc. amp..................................	DH, KL ..................................................	12	..
30 mg. per cc.............................	1 cc. amp..................................	BW, DH, KL ................................................	12	..
65 mg. per cc. ...........................	1 cc. amp..................................	BW, DH, KL................................................	6	..
1/2 gr. .......................................	tablet ........................................	BW ................................................	12	..
55	Emetine Bismuth Iodide ..............	1 gr...........................................	tablet ........................................	DH ................................................	25	1
2 gr. .........................................	tablet ........................................	DH ................................................	25	1
56	Entero-vioform..........................	0.25 G. .....................................	tablet ........................................	CB ................................................	100	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
57	Ephedrine Hydrochloride ..........	1/2 gr. per cc.............................	1 cc. amp..................................	AH, BD, BL, BW, DH, KL	6	1
3/4 gr. per cc. ............................	1 cc. amp. .................................	AH, BL, DH, KL .................................................	6	1
1/2 gr ........................................	hypo. Tab..................................	FA .................................................	20	1
1/4 gr........................................	tablet ........................................	AB, BW, DH, FA, HY, KL, RT, SI	100	1
1/2 gr ........................................	tablet ........................................	AB, BT, BW, DH, FA, HY, KL, PD, RT, SI.................................................	100	1
1 gr. ......................................... .	tablet ........................................	BT, HY, KL .................................................	100	1
58	Ephedrine Sulphate .....................	1/2 gr. per cc.............................	1 cc. amp..................................	AH .................................................	6	1
5% ...........................................	1 cc. amp. .................................	LY .................................................	6	1
3/8 gr ........................................	capsule .....................................	FA .................................................	40	1
3/4 gr ........................................	capsule .....................................	LY .................................................	40	1
1/2 gr ........................................	hypo. Tab..................................	LY .................................................	20	1
1/4 gr ........................................	tablet ........................................	HY, PD, RT .................................................	100	1
1/2 gr ........................................	tablet ........................................	FA, HY, PD, RT ................................................. .	100	1
59	Ergometrine Maleate..................	0.2 mg. per cc............................ ..	1 cc. amp..................................	LY .................................................	6	..
0.5 mg. per cc. ..........................	1 cc. I.M. amp...........................	AH, BD, BL, BW, FM .................................................	6	..
0.125 mg. per cc. ......................	1 cc. I.V. amp............................	BD, BW .................................................	6	..
0.2 mg.......................................	tablet ........................................	LY .................................................	25	..
0.5 mg. .....................................	tablet ........................................	BD, BT, BW .................................................	25	..
60	Ergot (Prepared)............................	................................................	1 cc. amp.................................. ..	PD .................................................	6	..
2½ gr.........................................	capsule .....................................	OP .................................................	25	1
2½ gr. .......................................	tablet ........................................	DH .................................................	25	1
4 gr. .........................................	tablet ........................................	DH, HY .................................................	25	1
61	Ergotamine Tartrate..................	................................................	0.5 cc. amp...............................	SZ .................................................	6	..
................................................	1 cc. amp..................................	SZ .................................................	6	..
1 mg. ........................................ .	tablet ........................................	SZ .................................................	15	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
62	Ergotoxine Ethanesulphonate	0.5 mg.......................................	tablet ........................................	BW ..........................................	25	..
63	Ethopropazine Hydro chloride	50 mg........................................	tablet ........................................	MB ..........................................	100	1
64	Ethyl Biscoumacetate ..........	300 mg......................................	tablet ........................................	GE ...........................................	100	..
65	Ethylidene Dicoumarin ........	100 mg......................................	tablet ........................................	NS ............................................	50	1
66	Examen ...................................	................................................	1 cc. amp..................................	GL ...........................................	12	1
.................................................	5 cc. amp..................................	GL ...........................................	1	1
67	Exatrope ................................	.................................................	2 cc. amp. .................................	GL ...........................................	12	1
.................................................	12 cc. amp................................	GL ...........................................	1	1
68	Gas Gangrene Antitoxin (Oedematiens)	10,000 U...................................	amp. .........................................	CS ............................................	3	1
69	Gas Gangrene Antitoxin	4,000 U.....................................	amp. .........................................	CS ............................................	3	1
(Perfringens)	10,000 U...................................	amp..........................................	BW, CS ....................................	10	1
70	Gas Gangrene Antitoxin	3,000 U. perfringens..................	.................................................
(Polyvalent)	1,500 U. septique......................	1 amp. ......................................	CS ............................................	2	1
1,000 U. oedematiens................
7,500 U. perfringens..................
3,750 U. septique......................	1 amp. ......................................	CS ............................................	2	1
2,500 U. oedematiens................
71	Gas Gangrene Antitoxin (Septique)	5,000 U.....................................	amp. .........................................	CS ............................................	2	1

First Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.
72	Glyceryl Trinitrate...................	1/100 gr ....................................	hypo. tab...................................	PD .................................................	50	1
1/200 gr ....................................	tablet ........................................	DH, FA, HY, SI .................................................	50	1
1/150 gr ....................................	tablet ........................................	HY .................................................	50	1
1/130 gr ....................................	tablet ........................................	DH, SI .................................................	50	1
1/100 gr ....................................	tablet ........................................	BW, DH, FA, HY, SI .................................................	50	1
1/65 gr......................................	tablet ........................................	DH, SI ................................................. ..	50	1
1/50 gr ......................................	tablet ........................................	HY .................................................	50	1
73	Hartmann’s Solution ...........	................................................	1 litre bottle ..............................	DH .................................................	2	1
74	Hartmann’s Solution with	5% ...........................................	1 litre bottle ..............................	DH .................................................	2	1
Dextrose	10% .........................................	1 litre bottle ..............................	DH .................................................	2	1
75	Heparin, Injection of .............	1,000 U, per cc..........................	5 cc. vial ...................................	BD, BT, EV, RO .................................................	5	..
1,000 U. per cc..........................	10 cc. vial .................................	AB .................................................	1	..
5,000 U. per cc. ........................	5 cc. vial ...................................	BD, BT. EV, RO .................................................	1	..
25,000 U. per cc........................	5 cc. vial ...................................	BT, EV .................................................	1	..
76	Heparin Retard, Injection of	20,000 U. per 2 mil. ..................	2 mil. amp.................................	BT .................................................

capsule ................................	LE ............................	16	..	endocarditis-streptococcus fae-
100 mg......................	vial................................	LE ............................	6	..	calis
Staphylococcal infections which do not respond to penicillin
Pneumonia which has not responded to penicillin nor to sulphonamides
Psittacosis
Urinary tract infections due to streptococcus faecalis
2	Calcium Para-aminosalicylate	1.5 G.........................	cachet .................................	KL, WA ..............................	200	1	Tuberculosis
2.0 G. .......................	cachet ................................	WA ............................	200	1
5 gr ...........................	tablet ................................	WA ............................	200	1
7½ gr ........................	tablet ................................	KL, WA .............................	200	1
.................................	100 G. tin ................................	WA ............................	1	1
.................................	400 G. tin ................................	WA ............................	1	1
3	Caramiphen Hydrochloride	0.05 G.......................	tablet ................................	GE ............................	100	1	Parkinsonism
4	Chloramphenicol ..................	0.125 G. ...................	capsule ................................	PD .............................	12	..	Typhoid fever
0.25 G.......................	capsule ................................	PD............................	12	..	Brucellosis
Typhus and other rickettsial diseases
Influenzal meningitis
Granuloma inguinale

Second Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
4—contd..	Chloramphenicol—continued.
Lymphogranuloma venereum
Whooping cough (haemophilus pertussis)
Infections due to haemophilus influenza
Acute laryngo-tracheo-bronchitis Salmonella infections
Severe gastro-enteritis in children
Staphylococcal infections that do not respond to either penicillin or aureomycin
Urinary tract infections due to gram negative bacilli that do not respond to sulphonamides
Meningitis due to bacterium coli if other forms of treatment are unsuccessful
5	Chloramphenicol Palmitate	0.125 G. per 4 cc.	60 cc. bottle	PD ...................................	1	..	Any disease or purpose specified in this column in relation to chloramphenicol
6	Cortisone Acetate ................	25 mg...............................	tablet .........................	AN, BD, BT, DH, RL, SC	40	1	Acute rheumatic carditis Addison’s disease
25 mg. per cc...............................	20 cc. vial .........................	DH, SO ...................................	1	..	Total adrenalectomy
50 mg. per cc...............................	10 cc. vial .........................	SC ...................................	1	..
7	Deoxycortone Acetate, Aqueous Injection of	5 mg...............................	amp.........................	CB, SC ...................................	4	..	Addison’s disease
50 mg...............................	amp.........................	CB, SC ...................................	1	..

Second Schedule—continued.

Item Number	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
8	Deoxycortone Acetate,	25 mg........................	amp...........................	CB ..................................	1	..	Addison’s disease
Aqueous Suspension of	50 mg........................	amp...........................	CB ..................................	1	..
9	Deoxycortone Acetate, Oily	2 mg. .........................	amp...........................	OR ..................................	4	..	Addison’s disease
Injection of	5 mg. .........................	amp...........................	BD, CB, OR, SC ..................................	4	..
10 mg........................	amp...........................	BD, CB, OR, SC ..................................	4	..
50 mg........................	implant..........................	BD, OR ..................................	1	..
100 mg................................... .	implant..........................	BD, CB, OR, SC ..................................	1	..
5 mg. per cc...............	5 cc. vial..........................	OR ..................................	1	..
10 mg. per cc.............	10 cc. vial..........................	CB, OR..................................	1	..
10	Dienoestrol ...........................	5 mg. .................................. .	tablet ..........................	AN, BD, DH, KL..................................	100	1	Carcinoma of the prostate
10 mg........................	tablet ..........................	KL ..................................	100	1	Mammary carcinoma
11	Dihydrostreptomycin ..........	1 G............................	vial ..........................	AN, BD, DN, GL, SI, SP, ST...............................	5	3	Any disease or purpose specified in this column in relation to streptomycin, but only if the person being treated for that disease or purpose is allergic to streptomycin
12	Folic Acid ...............................	15 mg. per cc.............	1 cc. amp...........................	AN, KL, LE ..................................	12	..	Sprue or the sprue-like syndrome
5 mg..........................	tablet ..........................	AN, CM, HY, KL, PD, SI	100	1
13	Isoniazid .................................	50 mg. .......................	tablet ..........................	AN, DH, HA, HT, HY. KL, MB, NS, RO, SC, SI	100	1	Tuberculosis
100 mg. .....................	tablet ..........................	MB, RO ..................................	100	1

Second Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
14	Pancreatin .............................	5 gr............................	tablet .................	OP, PD .................................	100	..	Fibrocystic disease of the pancreas
15	Para-aminosalicylic Acid ....	0.3 G..........................	tablet .................	CO, DH, HY, KL SI.................................	200	1	Tuberculosis
0.5 G..........................	tablet .................	AN, DH, HA, HY, KL, SI..............................	200	1
16	Phenindamine Tartrate.........	25 mg.........................	tablet .................	RO.................................	100	1	Parkinsonism
17	Progesterone, Injection of...	5 mg. .........................	Amp..................	BD, BT, CB, FM, KL, OR, SC..............................	6	..	Threatened abortion
10 mg.........................	amp. .................	BD, CB, FM, KL, OR, SC..............................	6	..
20 mg.........................	I. V. amp............	SC.................................	3	..
18	Quinine Bisulphate................	5 gr............................	tablet .................	BW, DH, FA, HY, PD	100	1	Malaria
19	Quinine Hydrochloride.........	3 gr. per cc.................	1 cc. amp...........	DH.................................	6	1	Malaria
6¼ gr. per cc..............	1 cc. amp...........	DH.................................	6	1
9¼ gr. per 2 cc............	2 cc. amp...........	DH.................................	6	1
15½ gr. per 2 cc..........	2 cc. amp...........	DH.................................	6	1
5 gr. ..........................	capsule .............	PD .................................	100	1
5 gr. ..........................	tablet .................	DH.................................	100	1
20	Quinine Hydrochloride ........	5 gr............................	tablet .................	BW, DH .................................	100	1	Malaria
21	Quinine Sulphate ...................	5 gr............................	tablet .................	DH, HY, SI .................................	100	1	Malaria

Second Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form or Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
22	Sodium Para-aminosalicylate	1.5 G.......................	cachet .......................	AN, BT, HT, KL, WA, WB	200	1	Tuberculosis
2.0 G.......................	cachet.......................	WA ..............................	200	1
0.5 G.......................	capsule.......................	HA ...............................	200	1
5 gr.........................	tablet .......................	CB, CM, DH, HY, KL, SI, WA	200	1
7½ gr ......................	tablet .......................	AN, BT, CB, CM, DH, HA, HT, HY, KL, SI, WA	200	1
20% .......................	10 cc. vial.......................	AN, HT, KL, WA	6	..
23	Stilboestrol ..........................	1 mg........................	amp.......................	AH, BD, DH ..	6	..	Carcinoma of the prostate
5 mg........................	amp.......................	AH, BD, BW, DH, KL	6	..	Mammary carcinoma
1 mg........................	Tablet.......................	AN, BD, BW, DH, FA, HA, HY, RT, SI	100	1
5 mg................................ ..	tablet .......................	AN, BD, BW, DH, FA, HA, HY, KL, RT, SI	100	1
10 mg......................	tablet .......................	CM, KL ........................	100	1
24	Streptomycin .........................	1 G ......................... .	vial .......................	AH, AN, BD, BW, DN, EV, GL, IC, MB, ST	5	3	Infections due to haemophilus influenza
Chancroid
Pneumonia due to bacillus Friedlander
Acute tuberculosis
Acute exacerbations in chronic tuberculosis
Salmonella infections

Second Schedule—continued.

Item Number.	Name or Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
24—contd.	Streptomycin—continued.	Bacillary dysentery not responding to sulphonamides
Surgical conditions of the bowel and of the thoracic organs
Tularaemia
Infections due to pseudomonas pyocyaneus
25	Terramycin.................................	50 mg........................	capsule ..........................	PF ..................................	25	..	Acute amoebic dysentery
100 mg......................	capsule ..........................	PF..................................	25	..	Acute and sub-acute bacterial endocarditis—streptococcus faecalis
250 mg......................	capsule ..........................	PF..................................	16	..	Staphylococcal infections which do not respond to penicillin
50 mg. ......................	tablet ..........................	PF..................................	25	..	Pneumonia which has not responded to penicillin nor to sulphonamides
100 mg......................	tablet ..........................	PF ..................................	25	..	Psittacosis
250 mg......................	tablet ..........................	PF..................................	16	..	Urinary tract infections due to streptococcus faecalis
100 mg......................	vial..........................	PF..................................	6	..
250 mg. per 10 cc.	10 cc. vial ..........................	PF..................................	6	..
26	Terramycin Oral Suspension	0.25 G. per 5 cc.	1 fl. oz. bottle..........................	PF..................................	1	..	Any disease or purpose specified in this column in relation to terramycin
27	Testosterone...............................	100 mg......................	implant ..........................	BD, CB, OR, SC ..................................	1	..	Mammary carcinoma
150 mg......................	implant ..........................	OR ..................................	1	..	Castration
200 mg......................	implant ..........................	OR..................................	1	..

Second Schedule—continued.

Item Number.	Name of Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
28	Testosterone, Methyl ..........	25 mg. ...............................	tablet .................	AN, BD, BS, BT, CS, HY, KL, OR, SC	25	1	Mammary carcinoma Castration
50 mg...............................	tablet .................	AN, BD, BS, BT, HY, KL, OR, SC	25	1
29	Testosterone Oenanthate, Injection of	250 mg. per cc. ...............................	1 cc. amp...........	SC ................................	1	..	Mammary carcinoma Castration
30	Testosterone Phenyl Propionate, Injection of	50 mg. per cc................................	1 cc. amp........................... .	OR................................	3	..	Mammary carcinoma
50 mg. per cc................................	5 cc. vial ...........	OR ................................	1	..	Castration
31	Testosterone Propionate, Injection of	25 mg. per cc................................	1 cc. amp...........	AH, AN, BD, BS, BT, BW, CB, FM, KL, OR, SC..	12	..	Mammary carcinoma Castration
50 mg. per cc................................	1 cc. amp. .........	AH, BD, BS, CB, PM, OR, SC.............................	12	..
50 mg. per cc................................	10 cc. vial .........	CB, KL, OR, SC ............	1	..
100 mg. per 2 mil............................... .	2 mil. amp..........	BD, PM, OR, SC ...........	1	..
100 mg...............................	implant .............	BD ................................	1
32	Tetracycline ...............................................	50 mg...............................	capsule .............	LE ................................	25	..	Any disease or purpose specified in this column in relation to aureomycin
100 mg................................	capsule .............	LE ................................	25	..
250 mg. .................................	capsule .............	LE ................................	16	..
50 mg...............................	tablet .................	PF .................................	25	..
100 mg...............................	tablet .................	PF .................................	25	..
250 mg...............................	tablet .................	PF .................................	16	..
100 mg...............................	vial....................	LE ................................	6	..

Second Schedule—continued.

Item Number.	Name of Formula.	Strength.	Form of Unit.	Brand.	Maximum Quantity or Number of Units.	Number of Repeats.	Disease or Purpose.
33	Vitamin B12, Injection of ..	10γ per cc..................	1 cc. amp. ..........................	BD, DH .................................	12	1	Established megalocytic anaemias
15γ per cc..................	1 cc. amp..........................	PD .................................	12	1
20γ per cc..................	1 cc. amp..........................	AH, AN, BD, BL, BT, BW, CK, CM, DH, EV, GL, IC, KL, NS, SI, ST, VM.............................	12	1
50γ per cc. ................	1 cc. amp..........................	AH, BD, BL, BT, BW, CK, DH, EV, GL, IC, NS, VM.............................	6	1
100γ per cc................	1 cc. amp..........................	AH, AN, BD, BL, BT, BW, CK, CM, EV, GL, IC, KL, PD, SI, VM.............................	1	1
100γ per cc................	10 cc. vial..........................	CM .................................	1	..
200γ per cc ...............	1 cc. amp...........................	BT ..................................	1	..
1,000γ per cc.............	1 cc. amp...........................	AN, CM, GL ................................. .	1	..
1,000γ per cc.............	10 cc. vial..........................	CM .................................	1	..

THIRD SCHEDULE.

Reg. 10.

Pensioner Benefits Additional to those Covered by Monograph in the British Pharmacopoeia.

Item No.	Name or Formula of Drug or Medicinal Preparation.
1	Acetonum B.P.C.
2	Acetum Scillae
3	Acid Hydrocyanicum Dilutum B.P.C.
4	Acid Sulphuricum Dilutum B.P.C.
5	Acidum Hypophosphorosum Dilutum
6	Acriflavina
7	Adeps
8	Adeps Benzoinatus
9	Aethylenum
10	Agar
11	Amidopyrina
12	Ammonii Bromidum B.P.C.
13	Aqua (Potable Water)
14	Aqua Anisi B.P.C.
15	Aqua Chlorbutolis A.P.F.
16	Argentoproteinum Mite B.P.C.
17	Balsamum Peruvianum
18	Betanaphthol
19	Caffeina Citrata B.P.C.
20	Caffeina et Sodii Benzoas
21	Calcii Mandelas
22	Cera Flava
23	Chiniofonum
24	Chromii Trioxidum
25	Codeina
26	Cremor Penicillini Sterilisatus
27	Dicoumarol
28	Ephedrinae Sulphas B.P.C.
29	Extractum Colchici Siccum
30	Extractum Colocynthidis Compositum
31	Extractum Ergotae Liquidum
32	Extractum Fellis Bovini
33	Extractum Glycyrrhizae
34	Extractum Hepatis Liquidum
35	Extractum Krameriae Siccum
36	Extractum Senegae Liquidum
37	Ferri Carbonas Saccharatus
38	Glycerinum Acidi Borici
39	Glycerinum Boracis
40	Hexoestrol
41	Hydrargyrum cum Creta
42	Infusum Aurantii
43	Infusum Aurantii Concentratum
44	Infusum Buchu B.P.C.
45	Infusum Calumbae
46	Infusum Calumbae Concentratum
47	Infusum Calumbae Recens
48	Infusum Caryophylli
49	Infusum Caryophylli Concentratum
50	Infusum Senegae
51	Infusum Senegae Concentratum
52	Infusum Sennae
53	Infusum Sennae Concentratum
54	Injectio Bismuthi Salicylatis
55	Injectio Caffeinae et Sodii Benzoatis
56	Injectio Oestradiolis Dipropionatis
57	Injectio Penicillini Oleosa

Third Schedule—continued.

Item No.	Name or Formula of Drug or Medicinal Preparation.
58	Injectio Physostigminae Salicylatis
59	Injectio Pituitarii Posterioris
60	Injectio Procainae et Adrenalinae Mitis
61	Injectio Sodii Citratis Anticoagulans
62	Injectio Sodii Citratis cum Dextroso
63	Injectio Strychninae Hydroehloridi
64	Injectio Sulphadiazinae Sodii
65	Iodoformum
66	Ipomoeae Resina
67	Laevulosum
68	Linimentum Aconiti
69	Linimentum Belladonnae
70	Liquor Ammoniae Aromaticus B.P.C.
71	Liquor Glycerylis Trinitratis B.P.C.
72	Liquor Magnesii Bicarbonatis
73	Magenta B.P.C.
74	Magnesii Phosphas B.P.C.
75	Mistura Aluminii Hydroxidi A.P.F.
76	Mel Depuratum
77	Mistura Sennae Composita
78	Oestradiolia Dipropionas
79	Oestronum
80	Oculentum Cocainae
81	Oculentum Physostigminae
82	Oleum Cajuputi
83	Oleum Cari
84	Oleum Citronellae B.P.C.

85	Oleum Cocois B.P.C.
86	Oleum Pini B.P.C.
87	Oxymel Scillae
88	Pelletierinae Tannas
89	Phenazonum
90	Pilula Aloes
91	Pilula Colocynthidis et Hyoscyami
92	Pilula Digitalis Co. B.P.C.
93	Pilula Ferri Carbonatis
94	Pilula Hydrargyri
95	Pilula Rhei Composita
96	Pilula Sodii Oleatis Co. A.P.F.
97	Pix Carbonis B.P.C.
98	Potassii Acetas
99	Potassii Chloras
100	Quininae et Aethylis Carbonas
101	Sapo Animalis
102	Sapo Durus
103	Sodii Carbonas Exsiccatus
104	Sodii Nitris
105	Sodii Phosphas Exsiccatus
106	Sodii Sulphas Exsiccatus
107	Spiritus Aetheris Nitrosi
108	Spiritus Cajuputi
109	Spiritus Camphorae
110	Strychnina B.P.C.
111	Sulphacetamidum
112	Sulphadiazina Sodium
113	Sulphonal
114	Suppositoria Acidi Tannici
115	Suppositoria Belladonnae
116	Suppositoria Bismuthi Subgallatis
117	Suppositoria Cocainae
118	Suppositoria Hamamelidis et Zinci Oxidi

Third Schedule—continued.

Item No.	Name or Formula of Drug or Medicinal Preparation.
119	Suppositoria Iodoformi
120	Suppositoria Morphinae
121	Suppositoria Phenolis
122	Syrupus Ferri Phosphatis Compositus
123	Syrupus Glucosi Liquidi
124	Syrupus Glyeerophosphatum Compositus A.P.F.
125	Syrupus Limonis Neutralis A.P.F.
126	Syrupus Pruni Serotinae
127	Syrupus Ruber A.P.F.
128	Syrupus Scillae
129	Tabellae Hexoestrolis
130	Tabellae Hydrargyri cum Creta
131	Tabellae Oestroni
132	Tabellae Phenazoni
133	Tabellae Potassii Chloratis
134	Tabellae Sodii Salicylatis
135	Tabellae Theobrominae Compositae B.P.C.
136	Tabellae Thiouracili
137	Theophyllina et Sodii Acetas
138	Talcum Purificatum B.P.C.
139	Thiouracilum
140	Tinctura Calumbae
141	Tinctura Capsici
142	Tinctura Catechu
143	Tinctura Cocci
144	Tinctura Gelsemii B.P.C.
145	Tinctura Lobeliae Aetherae
146	Tinctura Myrrhae
147	Tinctura Persionis A.P.F.
148	Tinctura Quassiae
149	Tinctura Scillae
150	Tinctura Senegae
151	Tinctura Strophanthi
152	Tinctura Tolutana
153	Tinctura Valerianae Ammoniata
154	Triethanolamina B.P.C.
155	Unguentum Capsici
156	Unguentum Gallae cum Opio B.P.C.
157	Unguentum Hydrargyri Compositum
158	Unguentum Hydrargyri Subchloridi
159	Unguentum Phenolis
160	Unguentum Zinci Oleatis
161	Unguentum Zinci Oxidi Aquosum
162	Xylenum B.P.C.

FOURTH SCHEDULE.

Reg. 12.

Maximum Quantities or Numbers of Units of Pensioner Pharmaceutical Benefits.

Form of Pensioner Pharmaceutical Benefit.	Maximum Quantity or Number of Units.
Applications ...................................................................................................	4 fl. oz.
Capsules .........................................................................................................	12
Collodions ......................................................................................................	120 min.

Fourth Schedule—continued.

Form of Pensioner Pharmaceutical Benefit.	Maximum Quantity or Number of Units.
Creams—
Creams of penicillin ....................................................................................	½ oz.
Other creams ..............................................................................................	4 oz.
Draughts .........................................................................................................	4 fl. oz.
Dusting powders .............................................................................................	4 oz.
Ear drops ........................................................................................................	1 fl. oz.
Elixirs .............................................................................................................	4 fl. oz.
Emulsions ......................................................................................................	16 fl. oz.
Enemas...........................................................................................................	4 fl. oz.
Extracts, fluid .................................................................................................	4 fl. oz.
Extracts of malt ..............................................................................................	1 lb.
Extracts of malt with cod liver oil ....................................................................	1 lb.
Eye drops .......................................................................................................	120 min.
Eye lotions .....................................................................................................	6 fl. oz.
Eye ointments—
Eye ointments of penicillin ..........................................................................	60 gr.
Other eye ointments ....................................................................................	¼ oz.
Gargles and mouth washes ..............................................................................	8 fl. oz.
Gelatins ..........................................................................................................	4 oz.
Glycanths .......................................................................................................	½ oz.
Glycerines ......................................................................................................	2 fl. oz.
Inhalations ......................................................................................................	2 fl. oz.
Injections—
Ampoules ...................................................................................................	6
Vials ...........................................................................................................	1
Irrigations .......................................................................................................	8 fl. oz.
Insufflations ...................................................................................................	1 oz.
Linctuses ........................................................................................................	3 fl. oz.
Liniments .......................................................................................................	4 fl. oz.
Lotions ...........................................................................................................	8 fl. oz.
Lozenges ........................................................................................................	25
Mixtures .........................................................................................................	8 fl. oz.
Nasal drops ....................................................................................................	½ fl. oz.
Ointments—
Ointments of penicillin ................................................................................	1 oz.
Other ointments ..........................................................................................	2 oz.
Paints .............................................................................................................	1 fl. oz.
Pastes .............................................................................................................	2 oz.
Pessaries .........................................................................................................	6
Pills ................................................................................................................	50
Poultices .........................................................................................................	1 lb.
Powders for internal use ..................................................................................	4 oz.
Powders, individually wrapped ........................................................................	12
Soaps .............................................................................................................	4 fl. oz.
Solutions for internal use .................................................................................	1 fl. oz.
Solutions for external use ................................................................................	4 fl. oz.
Sprays ............................................................................................................	½ fl. oz.
Suppositories ..................................................................................................	12
Syrups ............................................................................................................	8 fl. oz.
Tablets—
Tablets of phenobarbitone ............................................................................	100
Tablets of phenobarbitone sodium ................................................................	100
Other tablets ...............................................................................................	25
Tinctures ........................................................................................................	1 fl. oz.

FIFTH SCHEDULE.

Reg. 13.

Pharmaceutical Benefits that may be obtained by Medical Practitioners for purpose of Section 93.

Number of Pharmaceutical Benefit Corresponding to Number in First Schedule.	Name or Formula of Pharmaceutical Benefit.	Form of Unit.	Maximum Quantity or Number of Units.
2	Adrenalin Hydrochloride, Solution	Ampoule ................................................................................................................	6
of	Bottle ................................................................................................................	1
41	Digoxin .........................................................	Ampoule ................................................................................................................	12
Bottle ................................................................................................................	1
Tablet ................................................................................................................	100
43	Dihydromorphinone .........................................................	Ampoule ................................................................................................................	4
Hypodermic Tablet ................................................................................................................	20
Tablet ................................................................................................................	20
48	Diphtheria Antitoxin .........................................................	Ampoule ................................................................................................................	6
107	Morphine Sulphate .........................................................	Ampoule ................................................................................................................	6
Hypodermic Tablet ................................................................................................................	40
108	Morphine with Atropine .........................................................	Ampoule ................................................................................................................	6
Hypodermic Tablet ................................................................................................................	40
126	Penicillin, Procaine, Aqueous Suspension of	Vial ................................................................................................................	12
133	Pethidine Hydrochloride .........................................................	Ampoule ................................................................................................................	6
Tablet ................................................................................................................	25
145	Pituitary (Posterior Lobe), Injection of	Ampoule ................................................................................................................	12
177	Sulphonamides, Mixed, (B)—Three Sulphonamides	Tablet ................................................................................................................	100

SIXTH SCHEDULE.

Form A.

Reg. 5.

Commonwealth or Australia.

National Health Act 1953.

APPLICATION FOR APPROVAL AS A PHARMACEUTICAL CHEMIST.

(By a Registered Pharmaceutical Chemist.)

*I,			of ,
We,
trading as			, hereby apply for approval as a
pharmaceutical chemist under the National Health Act 1953 in respect of premises situated at
*I,		hereby declare that	*I am		are a pharmaceutical	*chemist	registered as such
We,			we are			*chemists
under the law of the *State of			*Territory.
*I	further declare that		*I am	willing to supply on demand, at or from the
We			we are
premises specified above, pharmaceutical benefits in accordance with Part VII of the National
Health Act 1953 and the Regulations made under that Act.

Dated this day of , 19

(Signature of Applicant).

To the Director-General of Health,

Commonwealth of Australia.

* Strike out whichever is inapplicable.

Fifth Schedule—continued.

Form B.

Reg. 5.

Commonwealth of Australia.

National Health Act 1953.

APPLICATION FOR APPROVAL AS A PHARMACEUTICAL CHEMIST.

(By a Friendly Society, &c.)

I, of

the person authorized to make this application by

, which is a Friendly Society or body carrying on business for the benefit of members of a friendly society or friendly societies, hereby apply for approval of that Friendly Society or body as a pharmaceutical chemist under the National Health Act 1953, in respect of premises situated at

The Friendly Society or body is prepared to supply on demand, at or from its premises specified above, pharmaceutical benefits in accordance with Part VII. of the National Health Act 1953 and the Regulations made under that Act.

*I declare that the Friendly Society or body was carrying on the business of a pharmaceutical chemist on the first day of August, 1945.

Dated this day of , 19 .

(Signature of person authorized to make application).

To the Director-General of Health,

Commonwealth of Australia.

* Strike out if inapplicable.

Form C.

Reg. 5.

Commonwealth of Australia.

National Health Act 1953.

APPLICATION FOR APPROVAL AS A HOSPITAL AUTHORITY.

I, of ,

the person authorized to make this application by the *governing body / the proprietor of the

Hospital, which is a * private/public hospital,

hereby apply under the National Health Act 1953 for approval of that hospital authority for the purpose of supplying general pharmaceutical benefits to patients receiving treatment in or at that hospital.

The hospital authority is prepared to supply pharmaceutical benefits in accordance with Part VII. of the National Health Act 1953 and the Regulations made under that Act.

The dispensing of drugs and medicinal preparations at the hospital is performed by or under the direct supervision of. who

is a *medical practitioner./pharmaceutical chemist.

Dated this day of , 19 .

(Signature of person authorized to make application).

To the Director-General of Health,

Commonwealth of Australia.

* Strike out whichever is inapplicable.

Fifth Schedule—continued

Form D.

Reg. 6.

Department of Health.

APPROVED

PHARMACEUTICAL

CHEMIST.

National Health Act.

Form E.

Reg. 19 (4.).

Commonwealth of Australia.

National Health Act 1953.

APPLICATION FOR AUTHORITY TO PRESCRIBE CORTISONE ACETATE.

(By a Medical Practitioner.)

I, of ,

hereby apply under sub-regulation (4.) of regulation 19 of the National Health. (Pharmaceutical Benefits) Regulations for authority to write a prescription for Cortisone Acetate as prescribed as a general pharmaceutical benefit in the Second Schedule to those Regulations in the following strength, form of unit, brand and quantity or number of units:—

I certify that the pharmaceutical benefit is required for the treatment of

, who is suffering from , being a disease or purpose specified in that Schedule in relation to that pharmaceutical benefit, and that in my opinion there is no other drug available that would be equally effective in this case.

Dated this day of , 19 .

(Signature of Medical Practitioner).

To the Director-General of Health,

Commonwealth of Australia.

By Authority : L.F.Johnston, Commonwealth Government Printer, Canberra.